Accelerated Pharma (Accelerated Pharma) Debt-to-EBITDA : -3.41 (As of Mar. 2017)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Accelerated Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2017 was $3.69 Mil. Accelerated Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2017 was $1.23 Mil. Accelerated Pharma's annualized EBITDA for the quarter that ended in Mar. 2017 was $-1.44 Mil. Accelerated Pharma's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2017 was -3.41.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Accelerated Pharma's Debt-to-EBITDA or its related term are showing as below:

ACCP's Debt-to-EBITDA is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.71
* Ranked among companies with meaningful Debt-to-EBITDA only.

Accelerated Pharma Debt-to-EBITDA Historical Data

The historical data trend for Accelerated Pharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Debt-to-EBITDA Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Debt-to-EBITDA

N/A

-0.80

-1.49

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Debt-to-EBITDA	Get a 7-Day Free Trial			-	-1.67	-1.70	-2.68	-3.41

Competitive Comparison of Accelerated Pharma's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accelerated Pharma's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's Debt-to-EBITDA falls into.

Accelerated Pharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Accelerated Pharma's Debt-to-EBITDA for the fiscal year that ended in Dec. 2016 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(3.38	+	1.211)	/	-3.091
	=	-1.49

Accelerated Pharma's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2017 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(3.685	+	1.229)	/	-1.44
	=	-3.41

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2017) EBITDA data.

Accelerated Pharma (NAS:ACCP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Accelerated Pharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines